BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

BioLife Solutions reports record revenue and projects strong growth

BioLife Solutions delivered strong financial performance in Q4 2022, with record revenue and growth across key revenue platforms.
Despite challenges in operating expenses and gross margin, the company remains optimistic about future growth and profitability.
By focusing on high-margin revenues, supply chain enhancements, and allogeneic therapies, BioLife is strategically positioned for long-term success.

BioLife Solutions reports revenue growth and strategic business evaluation

BioLife Solutions reported solid Q1 2023 performance with revenue growth and improved gross margin, despite short-term EBITDA challenges.
The company is strategically evaluating underperforming businesses while focusing on high-margin recurring revenue streams for future growth.
CEO's balanced approach of maintaining strengths and exploring new projects signals a commitment to sustainable profitability and innovation.
BioLife's emphasis on efficiency and strategic planning positions it well for navigating market uncertainties and driving long-term success.

BioLife Solutions reports Q2 revenue decline, focuses on strategic growth

BioLife Solutions navigated challenges in Q2 2023 with a strategic focus on higher-margin streams and a strong pipeline for growth.
Despite a decrease in revenue and challenges in key markets, the company's divestiture plans and revenue guidance reflect confidence in future performance.
Analysts' concerns about capacity constraints and operational challenges highlight areas for improvement and strategic focus for BioLife Solutions.

BioLife Solutions faces revenue decline in Q3 but eyes market growth

BioLife Solutions navigated challenges in Q3 2023 with a decline in revenue and negative adjusted EBITDA, but remains optimistic about its market position and potential for revenue recovery. Strategic divestiture plans and a focus on core products aim to drive profitability and growth.

BioLife Solutions reports 11% revenue decrease in 2023

BioLife Solutions navigated revenue challenges in 2023, with a focus on higher margin revenue streams and operational efficiency.
Despite revenue declines, the company remains optimistic about future growth opportunities in the cell processing sector.
Proactive supply chain management and a diversified supplier base position BioLife well to mitigate risks and ensure operational continuity.
Strategic plans to divest underperforming product lines and optimize operations indicate a path towards improved financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash. , March 15, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided additional details on its growth expectations for the Company's SciSafe®  biostorage services platform.

BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market

One of its acquired companies, Sterling, could not cope with the rapidly rising demand and this generated substantial one-off costs, marring the figures.

Temporary Setbacks At BioLife

BOTHELL, Wash., March 1, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced Mike Rice, Chairman and CEO, Rod de Greef, President and COO, and Troy Wichterman, CFO, are scheduled to present at both the Cowen and KeyBanc Investor Conferences in March 2022.

BioLife Solutions to Attend and Present at Upcoming Investor Conferences

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results - Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

BOTHELL, Wash. , Feb. 28, 2022 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced unaudited financial results for the three and 12 months ended December 31, 2021 and introduced 2022 revenue guidance.

BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results

BOTHELL, Wash., Feb. 21, 2022 /PRNewswire/ --  BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2021 financial results will be released after market close on Monday, February 28 th.

BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022

PetIQ

PETQ vs. BLFS: Which Stock Is the Better Value Option?

PETQ or BLFS: Which Is the Better Value Stock Right Now?

Henderson, Nevada, Feb. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioLife Sciences (OTCPK: BLFE) is pleased to announce that it has finalized a definitive agreement (the “Agreement”) with Health Box LLC towards the 100% acquisition of the Arizona-based orthomolecular medicine and natural health products company.

BioLife Sciences Inc. (OTC Markets: BLFE) Announced Today That the Company Has Finalized a Definitive Agreement With Health Box LLC for the 100% Acquisition of the Orthomolecular Medicine and Natural Health Products Company

Incyte

Seagen

Try your hand at morphing science and business for a great investment opportunity in biotech.

Best Biotech Stocks to Invest in Now

BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.

BioLife Solutions Announces Preliminary 2021 Revenue of $119 Million, Up 148% Over 2020

BOTHELL, Wash., Jan. 4, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, today announced an extended collaboration with Seattle Children's Therapeutics, a venture at Seattle Children's, bringing cutting edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children.

BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing

BioLife Solution is enjoying robust growth years over years.

BioLife: Poised For Growth

BOTHELL, Wash., Dec. 16, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced a partnership with UNICEF to extend thermal stability of temperature-sensitive COVID-19 vaccines in developing communities in Africa, the Middle East and South America where limited power infrastructure and extreme environmental conditions make it difficult for most ULT freezers to remain operational.

UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines

BOTHELL, Wash., Nov. 17, 2021 /PRNewswire/ --  BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced it has ranked 353 in the 27th annual Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

BioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™

BOTHELL, Wash., Nov. 15, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the broader biopharma markets, today announced that it was named to Inc. Magazine's inaugural list of the 250 best-led companies in the United States.

BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies

BioLife Solutions, Inc. (BLFS) CEO Mike Rise on Q3 2021 Earnings Conference Call -Earnings Call Transcript

BOTHELL, Wash., Nov. 11, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced financial results for the three and nine months ended September 30, 2021.

BioLife Solutions Announces Third Quarter 2021 Financial Results

BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.

BioLife Solutions Announces Executive Management Changes

BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2021 financial results will be released after market close on Thursday, November 11 th.

BioLife Solutions to Report Third Quarter 2021 Financial Results and Provide Business Update on November 11, 2021

BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate BioLife Solutions, Inc. (BLFS) to Report a Decline in Earnings: What to Look Out for

BOTHELL, Wash., Oct. 26, 2021 /PRNewswire/ -- Biolife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for cell and gene therapies ("CGT"), and its biological material storage brand SciSafe, a multi-facility provider of storage services to the CGT and broader biopharma market, today announced the opening of a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, adjacent to the Schiphol Airport.

Biolife Solutions Supports Biostorage Best Practices Through SciSafe's "Centers of Excellence" With New World-Class Facility in Amsterdam

This company is preserving biological material and can help your portfolio grow.

Have $500? This Under-the-Radar Stock Could Make You Richer From the Biotech Boom

BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze media, evo cold chain management platform and SciSafe storage services with Stirling UltraCold freezers are all being utilized by this top 10 largest global pharmaceutical company to support the anticipated regulatory approval and commercial launch of a new CAR T-cell therapy.

BioLife Solutions Leverages Expanded Bioproduction Tools and Services Portfolio in Multipoint Engagement with Leading CAR T-Cell Developer

Aby Mathew, Exec VP And Chief Scientific Off at Biolife Solutions (NASDAQ:BLFS), made a large buy and sell of company shares on September 22, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Aby Mathew exercised options to purchase 20,000 Biolife Solutions shares at a price of $1.64 per share for a total of $32,800 on September 22.

News for BioLife Solutions Stock (BLFS)